beat revenu expect novaseq pull thru continu track
ahead expect consum genet servic also key beat
sequenc instrument revenu light forecast consist management
expect placement guidanc reiter fy guidanc increas early-in-
the-year preced analysi suggest bia upsid
stock conclus remain outperform see upward bia pt
confid outlook sustain mid-teen revenu growth
ep fortifi follow observ strong novaseq
consum revenu reiter novaseq placement guidanc multipl
sourc upsid pharma consum servic share current trade
ep forecast addit dcf support upsid
revenu y/i ahead consensu expect
upsid attribut servic revenu consum genet popul
sequenc servic gel instrument servic contract product revenu
better expect sequenc consum novaseq annual pull thru
microarray consum consum genet ahead
forecast off-set model weaker expect sequenc instrument
revenu said manag indic assum guidanc novaseq
placement guidanc year re-affirmed believ place
novaseq q/q
beyond robust revenu beat favor mix lower instrument delay oper
expens time revers bit lower expect tax rate drove ep
doubl y/i nearli better consensu specif gross
margin ahead expect oper margin
ahead expect
revenu growth expect approxim
point increas attribut beat manag would
provid quantit bridg explain balanc increas key compon
includ sequenc consum consum genetics/microarray
pharma partnership importantli manag indic reduc key
revenu guidanc assumpt fy guidanc increas
manag indic time dynam benefit ep
increas opportunist invest growth initi given increas confidence/
strength continu page
pleas see page report import disclosur
well posit maintain leadership expand high-end genet
tool research market drive robust growth nipt market increasingli displac
exist diagnost establish reimburs act arm dealer
elimin barrier sequenc becom increasingli use oncolog adjac
market believ factor continu translat robust doubl digit revenu
earn growth justifi premium valuat
nextseq key growth driver
continu evolv favor
novaseq unabl catalyz
nextseq placement continu increas
new instruments/kit surpris
strength nextseq placement
sourc revenu
expand use sequenc increas
becom much favor
concern build oper leverag
slow materi
hiseq bigger expect headwind
leader genet tool segment tool diagnost market
segment compani broad portfolio system consum analysi tool
design simplifi genet analysi address rang genom complex price
point throughput enabl research select best solut scientif
challeng market leader next gener sequenc increasingli focus
reproduct health includ nipt act arm dealer emerg oncolog
model preced early-in-the-year manag guidanc conservat
suggest bia upsid exampl believ guidanc assum continu
novaseq consumable/box momentum note revenu guidanc set
prior consensu ep guidanc provid
cowen compani
cowen vs consensu mm except revenu guidanc slightli q/qgross expect slightli reiter oper expect opex slightli ep helix dilut revenu metric mm except metricstot estim know placement declin q/q sequenc forecast attribut larg strong consum genet trend growth statement mm except growth lower expect tax rate drove ep per better expectedgrowth count expens much lower expect believ larg transitori model increas beyond sale dollar term manag like increas sg invest strength begin revenu favor mix time dynam drove oper margin exceed forecast almost sale believ consensu base discuss investor believ beat sell side expect total sequenc revenu good news sequenc consum revenu line forecast believ consensu expect bad news sequenc instrument revenu look light consensu believ consensu miss sequenc instrument forecast also like light consensu expect magnitud believ consensu sequenc consum revenu dead-on forecast believ ahead consensu key driver novaseq pull thru believ exceed annual consensu product revenu line forecast beat consensu expect rel model microarray product ahead forecast sequenc consum ahead forecast sequenc instrument light streetaccount consensu ahead forecast attribut almost fulli strong consum demand gel instrument servic contract also help drive sequenc servic revenu manag indic expect guidanc believ light consensu said expect novaseq placement slightli bt-ng placement manag indic better expect guidanc believ better consensu believ consensu sequenc consum revenu expect total consum sale still better forecast revenu almost ahead expect driver upsid consum genet revenu microarray product servic instrument sequenc servic annual novaseq consum pull thru estim novaseq placement light forecast line manag expect fy placement guidanc reiter gross margin better expect due larg mix increas instrument placement increas pharmaceut partnership revenu low margin expect pressur gm cowen
compani report cowen compani
yr cagrcomments/guidancetot revenu guidanc y/i q/q modestlyproduct inst servic includ nextbio sequenc array servic nipt biggest revenu growth y/i revenu growth guid y/i y/i product revenu growth fx impact guidanc full year salesproduct sequenc revenu growth total revenu growth microarray revenu growth total revenu growth cowen
compani report thomson eikon cowen compani
mm except per share guidancenet revenu guidanc slightli q/qreport expect slightli reiter declin q/q gener oper expect similar sale time delay also opportunist invest non-oper interest year includ helix loss attribut nci add earn per ep helix dilut gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit greater-than-expect reduct academ
govern research fund competit commerci avail potenti
disrupt technolog price pressur caus competit increas demand
lower-pr instrument run-tim cost neg regulatori dynam
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
